Clinical Trial

Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
A study to learn about the long-term safety and efficacy of giroctocogene fitelparvovec or fidanacogene elaparvovec in patients with hemophilia A or hemophilia B respectively, who have received treatment through prior participation in a Pfizer-sponsored clinical trial. Data collection and participant visits will be based on standard of care.
Protocol Amendment History 3 changes
notable Trial sites expanded: 19 -> 22 locations 2026-05-20
notable Trial sites expanded: 8 -> 19 locations 2026-05-13
notable Trial sites reduced: 17 -> 8 locations 2026-05-06
Trial Details
NCT Number NCT05568719
Lead Sponsor Pfizer
Conditions Hemophilia A, Hemophilia B
Enrollment 173 participants
Start Date 2022-12-28
Primary Completion 2040-02-25 (estimated)
Study Completion 2040-02-25 (estimated)
Updated on ClinicalTrials.gov 2026-05-27